CLS will be called Cytion
Fastest deliveries on the market
> 800 well characterized cell lines
Worldwide service – one hand, one partner
Visit cytion.com for your cell line needs

LNCaP Cell Line: A Key to Prostate Cancer Breakthroughs

The LnCaP cell line is a cornerstone in cancer research, particularly in the study of prostate cancer. Its widespread application in the field is attributed to its utility in understanding the biological underpinnings of prostate cancer and in assessing the efficacy of potential therapeutic interventions. This article aims to provide a foundational understanding of the LNCaP (Lymph Node Carcinoma of the Prostate) cell line, equipping researchers with the essential information required to commence work with this cell line.

Characteristics and Origin of LNCaP Cells

The LNCaP cell line, recognized for its relevance in prostate cancer research, exhibits unique characteristics and origins that are pivotal for researchers to understand:

  • Origin: The LNCaP cells were first isolated in 1977 from the metastatic lymph node of a 50-year-old Caucasian male with prostate cancer, specifically from the left supraclavicular region.

  • Androgen Sensitivity: These cells are characterized by their sensitivity to androgens, a feature that has facilitated the development of two significant sublines from the original LNCaP cells: LNCaP-G4, known for its high androgen sensitivity, and LNCaP-E9, distinguished by its low androgen sensitivity. These sublines provide a versatile tool for probing the nuances of prostate cancer.

  • Morphology: LNCaP cells are epithelial-like in shape and capable of growing either as aggregates or as solitary cells, offering a versatile model for studying cell-cell interactions and cancer cell morphology.

  • Size: The average diameter of LNCaP prostate cancer cells is approximately 18 µm, a detail that aids in the microscopic examination and characterization of these cells.

  • Chromosomal Makeup: The cell line is aneuploid, with a variable chromosomal number ranging between 76 and 91, reflecting the genetic instability often observed in cancer cells.

  • Tumorigenic Potential: When introduced into male athymic nude mice, LNCaP cells demonstrate a 58% frequency of forming subcutaneous tumors, underscoring their utility in in vivo models of prostate cancer.

The detailed understanding of LNCaP cells' origin, characteristics, and utility in research provides a solid foundation for scientists embarking on prostate cancer studies, facilitating informed experimental design and interpretation of results.

Prostate cells in SEM.

Culturing LNCaP Cells: Essential Guidelines

Embarking on research with LNCaP, a prominent prostate cancer cell line, necessitates a thorough understanding of its culturing fundamentals. The following points encapsulate the critical aspects to consider for the effective culture of LNCaP cells:

  • Population Doubling Time: LNCaP cells exhibit an average doubling time of 48 to 60 hours, indicating the period required for the cell population to double under optimal conditions.

  • Growth Characteristic: These cells are adherent, tending to grow in monolayers while forming distinctive cell clusters, a trait important for monitoring cell health and confluence.

  • Seeding Density: It is advisable to seed LNCaP cells at a density of 1-2 x 10^4 cells/cm^2. The protocol involves washing the cells with PBS, detaching them using Accutase, followed by centrifugation. The cells are then resuspended and cultured in fresh growth media within new flasks.

  • Optimal Growth Medium: The preferred medium for LNCaP culture is EMEM, enriched with 2.5 mM L-glutamine and 10% fetal bovine serum (FBS). To maintain optimal growth conditions, it's recommended to refresh the media every third day.

  • Cultivation Environment: LNCaP cells thrive in a humidified incubator set to 37°C with a 5% CO2 atmosphere, conditions that mimic the in vivo environment closely.

  • Cell Storage: For long-term preservation, LNCaP cells should be stored in the vapor phase of liquid nitrogen, ensuring their viability for future experiments.

  • Freezing and Thawing Techniques: Utilizing CM-1 or CM-ACF freezing medium, LNCaP cells should be frozen gradually to minimize thermal shock. Upon thawing, which is best done in a 37°C water bath until only a small ice clump remains, cells should be promptly resuspended in growth medium, centrifuged to remove the freezing medium, and then transferred to culture flasks.

  • Biosafety Considerations: Culturing LNCaP cells requires adherence to biosafety level 1 protocols, ensuring safe and effective handling practices.

These guidelines serve as a foundation for establishing and maintaining LNCaP cell cultures, facilitating robust and reproducible results in prostate cancer research endeavors.

LNCaP Cells at low and high confluency.

Pros and Cons of Using the LNCaP Cell Line

The LNCaP cell line, a cornerstone in prostate cancer research, presents a unique set of characteristics that confer both advantages and challenges in its application. This section delineates the salient benefits and potential drawbacks associated with LNCaP cells.

Advantages

  • Ease of Cultivation: LNCaP cells are notably user-friendly in terms of cultivation and maintenance within a laboratory setting. This accessibility has made them a preferred choice for various applications, including drug screening and pharmacological testing.

  • Androgen Sensitivity: A hallmark of LNCaP cells is their dependency on androgens, characterized by the expression of androgen receptors (AR). This trait makes them an invaluable in vitro model for exploring the dynamics of androgen-dependent prostate cancer, providing insights into the disease's progression and potential therapeutic targets.

Disadvantages

  • Growth Rate: One of the limitations of LNCaP cells is their relatively slow proliferation rate. This characteristic can pose challenges in experimental designs that require rapid cell growth or high throughput within a constrained timeframe.

  • Cell Aggregation: LNCaP cells have a propensity to form aggregates or clusters, which can introduce variability and complicate the interpretation of data in certain cell-based assays, particularly those relying on uniform cell distribution or single-cell analysis.

Understanding these attributes of the LNCaP cell line is crucial for researchers to leverage its benefits while mitigating the impact of its limitations, thereby optimizing the cell line's potential in advancing prostate cancer research.

Research Applications of Androgen-Sensitive LNCaP Cells

LNCaP cells, derived from human prostate cancer, serve as a critical tool in various research domains. Their utility stems from their androgen-dependent nature and the ability to model specific aspects of prostate cancer biology. Key applications include:

Prostate Cancer Research

Androgen Receptor Studies

LNCaP cells, like many prostate tumor cells, exhibit sensitivity to androgens, which are critical drivers of prostate cancer growth. This sensitivity is exploited therapeutically via androgen deprivation strategies, such as androgen ablation or the use of antiandrogens like flutamide. The efficacy of these therapies is often monitored through the suppression of specific antigens and the repression of cell proliferation. However, the emergence of resistant prostate cancer is a significant challenge, often following antiandrogen withdrawal, which can lead to metastatic disease.

Mutations play a pivotal role in the adaptation and resistance mechanisms of LNCaP cells. Point mutations, especially within the androgen receptor gene, have been identified and studied using techniques such as polymerase chain reaction (PCR) and transcriptomic analyses. These mutations can affect the cells' response to androgen deprivation and antiandrogen therapies, contributing to the complexity of treating advanced prostate cancer.

Drug Discovery

Therapeutic Screening

Research using LNCaP cells has expanded beyond traditional hormone therapies to explore novel treatments. The intracellular drug delivery aimed at targeting specific pathways within these cells, the cytotoxicities of compounds like ripl, and the effects of agents such as amygdalin and clorgyline have been subjects of interest. These studies aim to uncover new methods to halt the metastatic process, control cell cycle progression, and induce cell cycle arrest in prostate cancer cells, offering hope for more effective treatments against advanced and resistant forms of the disease.

Clinical Implications

The metastatic potential of LNCaP cells, particularly their ability to mimic the metastatic process to sites like the supraclavicular lymph node, makes them invaluable for studying prostate cancer's spread. Understanding the genomic and transcriptomic landscape of these cells, including the role of human genomic DNA in their behavior, is crucial for developing strategies to prevent or treat metastatic prostate cancer.

Elevate your research with our LnCaP cell line and its derivative LnCaP clone FGC

Resources and Research Insights on LNCaP Cells

Gaining access to high-caliber LNCaP cell lines and their detailed genetic and phenotypic data is crucial for researchers. Numerous biorepositories and scientific institutions offer these vital resources, empowering researchers to conduct thorough and significant studies in prostate cancer and related fields.

Noteworthy Research Publications Involving LNCaP Cells

The LNCaP cell line has been central to numerous impactful studies within the realm of prostate cancer research. Below are some notable publications that have utilized LNCaP cells as a key research model:

LNCaP Cells: Protocols, Tutorials, and More

LNCaP, a widely used prostate cancer cell line, is supported by an abundance of resources, including detailed culturing and transfection protocols:

FAQs on LNCaP cells

LNCaP cells are a human prostate cancer cell line derived from a metastatic lesion of lymph node origin. They are characterized by their androgen sensitivity and are extensively used in prostate cancer research.
LNCaP and VCaP cells are both prostate cancer cell lines but differ in their origins and characteristics. LNCaP cells are derived from a lymph node metastasis and are androgen-sensitive, while VCaP cells originate from a vertebral metastasis and have a higher expression of the TMPRSS2-ERG fusion gene, which is common in prostate cancer.

LNCaP, DU145, and PC3 represent different prostate cancer cell lines with distinct features:

  • LNCaP: Androgen-sensitive, derived from lymph node metastasis.
  • DU145: Androgen-independent, originating from a central nervous system metastasis.
  • PC3: Also androgen-independent, derived from a bone metastasis. PC3 and DU145 are more aggressive and less differentiated than LNCaP.
The doubling time of LNCaP cells typically ranges between 48 to 60 hours, varying with culture conditions.
LNCaP cells were isolated from a metastatic site in the lymph node of a 50-year-old Caucasian male with prostate cancer.
LNCaP cells are frozen using a cryoprotective agent, typically a solution containing DMSO and fetal bovine serum. Cells are gradually cooled to -80°C before long-term storage in liquid nitrogen vapor phase to ensure viability upon thawing.
Yes, LNCaP cells express the androgen receptor (AR), making them a valuable model for studying androgen-responsive aspects of prostate cancer.

References

  1. Castanares, M.A., et al., Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. The Prostate, 2016. 76(2): p. 215-225.
  2. Iguchi, K., et al., Isolation and characterization of LNCaP sublines differing in hormone sensitivity. Journal of andrology, 2007. 28(5): p. 670-678.
  3. Wei, C., et al., CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Molecular medicine reports, 2018. 17(2): p. 2901-2906.
  4. Gomes, I.M., et al., Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens. Medical Oncology, 2018. 35: p. 1-10.
  5. Tousi, M.S., et al., Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNCaP human prostate cancer cell lines. Journal of Pharmaceutical Analysis, 2021. 11(1): p. 108-121.

 

We have detected that you are in a different country or are using a different browser language than currently selected. Would you like to accept the suggested settings?

Close